REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Picca A, Touat M, Belin L, Gourmelon C, et al. Eur J Cancer 2024;202:114034.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Picca A, Touat M, Belin L, Gourmelon C, et al. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. Eur J Cancer 2024;202:114034.
PMID: 38537315